Healthcare utilization in individuals with late onset versus adult-onset Huntington’s disease
Objective: To assess healthcare utilization (HCU) among patients (pts) with late-onset Huntington’s disease (LoHD) versus adult-onset HD (AoHD) and non-HD controls. Background: HD typically manifests…Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease
Objective: Examine healthcare resource utilization (HRU) and costs among US Medicare beneficiaries with late-onset Huntington’s disease (LoHD). Background: Huntington’s disease (HD) is a genetic, neurodegenerative…Primary Palliative Care for Huntington Disease
Objective: To develop a pilot program integrating primary palliative care with interdisciplinary care for Huntington disease (HD). Goals: 1) train HD team members to facilitate…Reversible hemichorea due to contralateral anterior cerebral artery territory hypoperfusion
Objective: We report hemichorea due to hypoperfusion of the contralateral anterior cerebral artery (ACA) territory (including caudate nucleus and its connections) that reversed with revascularization.…Medically refractory Graves’ disease presenting as chorea and carbohydrate hyperphagia in a Kenyan adolescent
Objective: To report a unique case of adolescent-onset autoimmune hyperthyroidism presenting with chorea and carbohydrate hyperphagia (CH). Background: Autoimmune hyperthyroidism [Graves’ disease (GD)] can cause…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…Diabetes Mellitus in Huntington’s disease. The Argentinean perspective
Objective: to compare the prevalence of diabetes mellitus (DM) in a self-reported series of local Huntington disease (HD) participants in the ENROLL-HD registry with the…Characterizing US Healthcare Delivery in Huntington’s Disease (HD)
Objective: The HD-Net research survey aimed to assess care patterns among practice types in the U.S., to identify gaps in the provision of HD care.…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »